Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Sells $412,356.93 in Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 13,551 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $30.43, for a total value of $412,356.93. Following the sale, the chief executive officer now directly owns 418,519 shares in the company, valued at approximately $12,735,533.17. This trade represents a 3.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Cedric Francois also recently made the following trade(s):

• On Friday, January 17th, Cedric Francois sold 6,007 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $29.96, for a total transaction of $179,969.72.
• On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $28.70, for a total transaction of $179,288.90.

Apellis Pharmaceuticals Stock Up 1.2 %

Shares of APLS traded up $0.37 during trading hours on Thursday, reaching $30.76. 1,345,028 shares of the stock traded hands, compared to its average volume of 2,139,207. The company has a market cap of $3.83 billion, a price-to-earnings ratio of -15.15 and a beta of 0.94. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. Apellis Pharmaceuticals, Inc. has a 52 week low of $24.34 and a 52 week high of $71.90. The stock has a fifty day simple moving average of $31.95 and a 200 day simple moving average of $33.25.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $196.83 million during the quarter, compared to the consensus estimate of $200.00 million. During the same period last year, the firm earned ($1.17) EPS. The business’s revenue for the quarter was up 78.3% on a year-over-year basis. On average, equities analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.71 EPS for the current year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Wolverine Asset Management LLC bought a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter worth approximately $27,000. True Wealth Design LLC purchased a new position in Apellis Pharmaceuticals during the 3rd quarter valued at about $27,000. Capital Performance Advisors LLP purchased a new position in Apellis Pharmaceuticals in the third quarter worth about $56,000. KBC Group NV raised its holdings in Apellis Pharmaceuticals by 34.8% in the third quarter. KBC Group NV now owns 2,632 shares of the company’s stock worth $76,000 after buying an additional 679 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in Apellis Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock worth $130,000 after buying an additional 781 shares during the last quarter. Hedge funds and other institutional investors own 96.29% of the company’s stock.

Wall Street Analysts Forecast Growth

APLS has been the subject of several research analyst reports. Scotiabank decreased their price target on shares of Apellis Pharmaceuticals from $35.00 to $30.00 and set a “sector perform” rating for the company in a report on Wednesday, November 6th. Evercore ISI upgraded shares of Apellis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, October 31st. Robert W. Baird decreased their target price on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. Piper Sandler dropped their price objective on shares of Apellis Pharmaceuticals from $40.00 to $32.00 and set a “neutral” rating for the company in a research note on Wednesday, November 6th. Finally, Wells Fargo & Company dropped their price target on shares of Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 6th. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $46.71.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).